Skip to Content
Contact Form Map & Directions Videos

Category: Defective Drugs

Benicar – The Hidden Dangers

04/6/2015
Common Questions
BY

On January 9, 2015, the Department of Justice announced that Daiichi Sankyo, a Japanese corporation who has its United States headquarters in New Jersey, was fined $39 million as a result of violating the False Claims Act by paying kickbacks to physicians to induce them to prescribe drugs manufactured by […]

Read More

Levaquin Blamed for Neuropathy, and Other Serious Side Effects

03/30/2015
Articles
BY

A reported 100,000 Americans, including a 54-year-old Illinois man and 36-year-old North Carolina woman, have reported severe side effects from Levaquin, an antibiotic that packs enough pill power to kill anthrax. Levaquin, a drug classified in the fluoroquinolone family, is now undergoing another Food and Drug Administration evaluation because of the controversy. Twelve […]

Read More

FDA Drug Approvals off the Charts for 2014

03/17/2015
Articles
BY

New Medications Meet Unmet Patient Needs The Food and Drug Administration’s approval of 41 novel new drugs in 2014 made it a banner year for the pharmaceutical industry. The class of 2014 included biologicals, drugs that treat cancer and infectious diseases (bacterial, fungal, parasitic and viral) and therapeutic drugs. The […]

Read More

JPML Asked to Consolidate Benicar Lawsuits

12/28/2014
Defective Drugs
BY

Daiichi Sankyo, Inc. developed the prescription medication Benicar (Olmesartan Medoxomil) to treat high blood pressure. In April 2002, the U.S. Food and Drug Administration (FDA) approved Benicar. Since that time, it has become a widely prescribed blood pressure medication. However, researchers have discovered Benicar use has a high association with […]

Read More

Is mHealth “Big Pharma’s” Nemesis?

12/18/2014
Defective Drugs
BY

Marketing study after marketing study shows mobile is the future for all industries – “big pharma” included. But marketing study after marketing study also shows drug companies fall far behind in making their Web sites compatible with smartphones, tablets and other devices. One-third of Web sites belonging to 150 leading […]

Read More

“Big Pharma’s” Resistance To Go Mobile Multifaceted

12/16/2014
Articles
BY

The reasons the seemingly cutting-edge pharmaceutical industry lags behind in the mobile-application domain are far and wide, say medical marketers, who predict that, in the end, companies’ bottom lines, doctors’ choices and patient health will suffer. Let’s look at the facts: First, one-third of drug-makers’ Web sites are optimized for […]

Read More

Hear What Our Clients Have To Say

"Nick DeBellis obtained the maximum recovery of full insurance limits in the case we worked on. He is a true professional and recommend him to anyone in South Florida."
Posted By: Michael Geoffroy